natgillin/translations-raw huggingface dataset:
In general, expected signs and symptoms are those resulting from an exaggeration of paliperidone’s known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, QT prolongation, and extrapyramidal symptoms.
Na splošno lahko pričakujete znake in simptome, ki nastanejo kot posledica stopnjevanja znanih farmakoloških učinkov paliperidona, to je zaspanost in sedacijo, tahikardijo in hipotenzijo, podaljšanje intervala QT in ekstrapiramidne simptome.
In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.
Na splošno se parametri farmakokinetike febuksostata, ocenjeni v teh analizah, ujemajo s tistimi, ki so jih pridobili pri zdravih osebah, kar kaže, da so zdrave osebe ustrezne za oceno farmakokinetike/farmakodinamike pri bolnikih s protinom.
In general, however, higher levels of resistance resulted from the co–expression of greater numbers of substitutions at the eleven identified positions.
Na splošno je višjo stopnjo rezistence sprožila koekspresija večjega števila substitucij na enajstih ugotovljenih mestih.
In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti- estrogenic in rats and man and estrogenic in mice.
Na splošno pa imajo nesteroidni derivati trifeniletilena pri podganah in človeku predvsem antiestrogensko delovanje, pri miših pa estrogensko delovanje.
In general, inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe.
Na splošno, nepazljivo, nenamerno ali nenadzorovano zamenjevanje zdravil s takrolimusom v farmacevtskih oblikah, s takojšnjim ali podaljšanim sproščanjem, ni varno.
In general, PASI responses were achieved by Week 16 and were maintained through Week 32.
Na splošno so bolniki dosegli odzive PASI po 16 tednih, trajali pa so še po 32 tednih.
In general, rash manifests as a mild or moderate erythematous and acneiform rash, which may occur or worsen in areas exposed to sun.
Izpuščaj ima večinoma obliko blagega ali zmerno hudega eritematoznega in akneiformnega izpuščaja, ki se lahko pojavi ali poslabša na predelih, ki so izpostavljeni soncu.
In general, serotype- specific IgG GMCs were lower for preterm infants than term infants.
Na splošno so bile za serotip značilne ravni IgG GMC pri nedonošenčkih nižje kot pri donošenčkih.
In general, side effects in sJIA patients were of a similar type to those in adults with RA.
V splošnem so neželeni učinki, opaženi pri bolnikih s sJIA, podobni tistim pri bolnikih z revmatoidnim artritisom.
In general, taking too much Axura should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Axura ne sme imeti škodljivih posledic.
In general, taking too much Ebixa should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Ebixa ne sme imeti škodljivih posledic.
In general, taking too much Marixino should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Marixino ne bi smelo imeti škodljivih posledic.
In general, taking too much Memantine LEK should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Memantin LEK ne sme imeti škodljivih posledic.
In general, taking too much Memantine Merz should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Memantine Merz ne sme imeti škodljivih posledic.
In general, taking too much Memantine Mylan should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Memantin Mylan ne bi smelo imeti škodljivih posledic.
In general, taking too much Memantine ratiopharm should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Memantin ratiopharm ne sme imeti škodljivih posledic.
In general, taking too much Nemdatine should not result in any harm to you.
Na splošno zaužitje večjega odmerka zdravila Nemdatine ne sme imeti škodljivih posledic.
In general, the ADRs in pJIA and sJIA patients were similar in type to those see in RA patients, see section 4.8.
V splošnem so neželeni učinki pri bolnikih s pJIA in sJIA podobnega tipa kot tisti, ki so jih opazili pri bolnikih z revmatoidnim artritisom (glejte poglavje 4.8).
In general, the ADRs in sJIA patients were similar in type to those seen in RA patients, see section
V splošnem so neželeni učinki pri bolnikih s sJIA podobnega tipa kot tisti, opaženi pri bolnikih z revmatoidnim artritisom (glejte poglavje 4.8).
In general, the adverse effects of overdose are consistent with those listed in section 4.8. General supportive measures should be initiated in all cases of overdose.
Na splošno so neželeni učinki pri prevelikem odmerjanju enaki tistim, ki so navedeni v poglavju 4.8. V vseh primerih prevelikega odmerjanja je treba uvesti splošne podporne ukrepe.
In general, the adverse event profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition, as decrease in height percentile (mean percentile decrease of growth velocity of 9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment.
Na splošno je bil profil neželenih učinkov v omejeni proučevani populaciji otrok in mladostnikov, ki je bila vključena v študije, podoben profilu pri odraslih, čeprav se je pri njih pojavila dodatna skrb glede zaviranja rasti, saj so med zdravljenjem opažali zmanjšanje percentila telesne višine (srednje odstotno zmanjšanje hitrosti rasti za 9 percentilov) in telesne mase (srednje odstotno zmanjšanje za
In general, the adverse event profile in the limited paediatric population studied was similar to that observed in adults, although there is a paediatric specific concern regarding growth inhibition as decrease in height (mean percentile decrease of growth velocity of 9 %) and weight (mean percentile decrease of 13 %)
Na splošno je bil profil neželenih dogodkov v omejeni pediatrični populaciji, ki je bila vključena v študije, podoben profilu pri odraslih, se je pri njih pojavila dodatna skrb glede zaviranja rasti, saj so med zdravljenjem opažali zmanjšanje percentila telesne višine (srednje percentilno zmanjšanje hitrosti rasti za 9 %) in telesne mase (srednje percentilno zmanjšanje za 13 %) (glejte poglavje 4.4).
In general, the adverse event profile reported with overdose was comparable to recommended single doses of Silgard.
Profil neželenih dogodkov, o katerih so poročali pri prevelikem odmerjanju, je bil na splošno primerljiv s profilom pri priporočenem enkratnem odmerku cepiva Silgard.
In general, the adverse event profile reported with overdose was comparable to that observed with the recommended dose of HBVAXPRO.
Na splošno je bil profil neželenih učinkov pri prevelikem odmerjanju podoben kot med uporabo priporočenih odmerkov cepiva HBVAXPRO.
In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in frequency and type to those seen in adult patients (see below, Undesirable effects in adults).
Na splošno so bili neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom po vrsti in pogostnosti podobni tistim pri odraslih (glejte spodaj, Neželeni učinki pri odraslih).
In general, the dosage (infusion rate) should be adjusted to the activated partial thromboplastin time, aPTT.
Na splošno mora biti odmerjanje (hitrost indundiranja) prilagojena aktiviranemu parcialnemu tromboplastinskemu času (aPTT).
In general, the incidence of adverse reactions (especially “dizziness”) has been shown to be slightly higher in patients with a history of hypertension.
Incidenca neželenih učinkov (predvsem »omotica«) jenekoliko večja pri bolnikih s hipertenzijo v anamnezi.
In general, the lowest dose leading to a response should be given to you.
Praviloma mora bolnik uporabljati najmanjši učinkoviti odmerek.
In general, the safety profile for children and adolescents (≤18 years of age) is similar to the safety profile for adults.
Navadno je varnostni profil otrok in mladostnikov (starih 18 let) podoben varnostnemu profilu odraslih bolnikov.
In general, the safety profile for children and adolescents (≤18 years of age) is similar to the safety profile for adults.
Navadno je varnostni profil otrok in mladostnikov (starih 18 let) podoben varnostnemu profilu odraslih.
In general, the safety profile for children and adolescents (≤18 years of age) is similar to the safety profile for adults.
Navadno je varnostni profil otrok in mladostnikov (starih 18 let), podoben varnostnemu profilu odraslih bolnikov.
In general, the safety profile for children and adolescents (≤18 years of age) is similar to the safety profile for adults.
Navadno je varnostni profil otrok in mladostnikov(starih 18 let), podoben varnostnemu profilu odraslih bolnikov.
In general, the safety profile in the patients “at risk” was qualitatively similar to that in otherwise healthy adults/adolescents.
V splošnem je bil varnostni profil pri “ogroženih’’ bolnikih kakovostno podoben tistemu pri drugače zdravih odraslih /mladostnikih.
In general, the safety profile in the patients “at risk” was qualitatively similar to that in otherwise healthy adults/adolescents.
V splošnem je bil varnostni profil pri “ogroženih’’ bolnikih kakovostno podoben tistemu pri drugače zdravih odraslih/mladostnikih.
In general, the side effects in children and adolescents are similar to those seen in adults.
Na splošno rečeno so neželeni učinki pri otrocih in mladostnikih podobni kot pri odraslih.
In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.
Navadno so neželeni učinki pri bolnikih starih  18 let podobni neželenim učinkom pri odraslih.
In general, these events were not associated with renal dysfunction and resolved with hydration and temporary interruption of therapy (e.g., 1–3 days).
Na splošno ti dogodki niso bili povezani z motnjami delovanja ledvic.
In general, treatment-emergent adverse events tended to decrease over time, perhaps accounted for by amelioration of the underlying disease process.
Na splošno so se neželeni učinki, nastali zaradi zdravljenja, sčasoma zmanjšali, najverjetneje zaradi izboljšanja osnovnega bolezenskega stanja.
In general, when patients are transferred from injection to infusion therapy, it may be advisable to reduce the dosage by initiating the patient at 90% of the previous total daily dosage, with 40% as basal rate and 50% as boluses divided between the three main meals.
Na splošno utegne biti pri bolnikih, ki prehajajo z injekcijskega zdravljenja na zdravljenje z infuzijo, priporocljivo zmanjšati odmerek, tako da bolnik zacne z 90 % prejšnjega celotnega dnevnega odmerka, in sicer s 40 % kot bazalna infuzija in 50 % kot bolusi, razdeljenimi med tri glavne obroke.
In general, women with HIV should not breast-feed in order to avoid passing HIV to their infant through the milk.
Na splošno je priporočljivo, da ženske, okužene s HIV, ne dojijo svojih otrok, ker se virus lahko prenese na dojenčka z materinim mlekom.
In general, Xadago may be used with selective serotonin re-uptake inhibitors (SSRIs) at the lowest effective dose, with caution for serotoninergic symptoms.
Zdravilo Xadago je na splošno mogoče uporabljati s selektivnimi zaviralci ponovnega privzema serotonina (SSRI) v najmanjšem učinkovitem odmerku, pri čemer je treba biti pozoren na simptome serotoninergičnega sindroma.
In general, you will need to take special care to try and avoid effects of low blood pressure, such as fainting and dizziness:
Predvsem bodite pozorni, da ne pride do znakov nizkega krvnega tlaka, kot sta omedlevica in omotica:
In general, your treatment should continue for at least 14 days after the last day Candida was found in your blood.
Praviloma boste morali zdravilo dobivati vsaj še 14 dni po dnevu, ko so vam v krvi zadnjič našli
In genetic toxicity studies, vilanterol (as alpha-phenylcinnamate) and triphenylacetic acid were not genotoxic indicating that vilanterol (as trifenatate) does not represent a genotoxic hazard to humans.
Študije genotoksičnosti kažejo, da vilanterol (v obliki alfa-fenilcinamata) in trifenilocetna kislina nista genotoksična, to kaže, da vilanterol (v obliki trifenatata) za človeka ne pomeni genotoksične nevarnosti.
In genotype 1a, substitutions C316Y, M414T, Y448H, A553T, G554S, S556G/R, and Y561H in HCV NS5B reduced susceptibility to dasabuvir.
Pri genotipu 1a so substitucije C316Y, M414T, Y448H, A553T, G554S, S556G/R in Y561H v genu NS5B HCV zmanjšale občutljivost za dasabuvir.
In genotype 1a, substitutions M28T/V, Q30E/R, L31V, H58D, Y93C/H/N, and M28V + Q30R in HCV NS5A reduced susceptibility to ombitasvir.
Pri genotipu 1a so substitucije M28T/V, Q30ER, L31V, H58D, Y93C/H/N in M28V + Q30R v genu NS5A HCV zmanjšale občutljivost za ombitasvir.
In genotype 1b, substitutions C316N, C316Y, M414T, Y448H, and S556G in HCV NS5B reduced susceptibility to dasabuvir.
Pri genotipu 1b so substitucije C316N, C316Y, M414T, Y448H in S556G v NS5B HCV zmanjšale občutljivost za dasabuvir.
In genotype 4 replicons, single NS3 substitutions D168A/V reduced grazoprevir antiviral activity by 110- to 320-fold.
V replikonih genotipa HCV 4 je posamezna substitucija NS3 D168A/V zmanjšala protivirusno aktivnost grazoprevirja za 110- do 320-krat.
In genotype 4 replicons, single NS5A substitutions L30S, M31V, and Y93H reduced elbasvir antiviral activity by 3- to 23-fold.
V replikonih genotipa HCV 4 so posamezne substitucije NS5A L30S, M31V in Y93H zmanjšale protivirusno aktivnost elbasvirja za 3- do 23-krat.
In genotype 4a, resistance to paritaprevir or ombitasvir by variants in NS3 or NS5A, respectively, selected in cell culture were phenotypically characterised.
Pri genotipu 4a so fenotipsko opredelili odpornost proti paritaprevirju ali ombitasvirju zaradi variant NS3 ali NS5A, izbranih v celični kulturi.
In girls with Turner syndrome:
Deklice s Turnerjevim sindromom:
In GIST patients (study B2222), 6.8% of grade3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade3 or 4 AST (aspartate aminotransferase) elevations were observed.
Pri bolnikih z GIST (študija B2222) so ugotovili 6,8 % zvišanj ALT (alanin-aminotransferaza) stopnje 3 ali 4 in 4,8 % zvišanj AST (aspartat-aminotransferaza) stopnje 3 ali 4.
In GIST patients ‘cardiac failure’, ‘cardiac failure congestive’ or ‘left ventricular failure’ were reported in 1.2% of patients treated with sunitinib and 1% of patients treated with placebo.
Pri bolnikih z GIST je bilo ''srčno popuščanje'', ''kongestivno srčno popuščanje'' oz. ''levostransko srčno popuščanje'' opisano pri 1,2 % bolnikov, ki so prejemali sunitinib, in pri 1 % bolnikov, ki so prejemali placebo.
In GIST the investigational medicinal product was discontinued for treatment-related adverse reactions in 4 % of patients.
Pri bolnikih z GIST so prekinitev zdravljenja z raziskovanim zdravilom zaradi neželenih učinkov, povezanih z imatinibom, zabeležili pri 4 % bolnikov.
In GIST the study medicinal product was discontinued for medicinal product-related adverse reactions in 4% of patients.
Pri GIST so preskušano zdravilo ukinili zaradi neželenih reakcij, povezanih z zdravilom, pri 4 % bolnikov.
In GO-AFTER, the percentage of patients achieving an ACR 20 response was greater for patients receiving Simponi than for patients receiving placebo regardless of the reason reported for discontinuation of one or more prior anti-TNF therapies.
V študiji GO-AFTER je bil odstotek bolnikov, ki so dosegli odziv ACR 20, večji pri bolnikih, ki so prejemali zdravilo Simponi kot pri tistih, ki so prejemali placebo, ne glede na prijavljeni razlog za ukinitev enega ali več prej uporabljenih zaviralcev TNF.
In GO-AFTER, the primary endpoint was the percentage of patients achieving an ACR 20 response at week 14.
Primarni opazovani dogodek je bil delež bolnikov, ki so v 16. tednu dosegli odziv ASAS 20.
In GO-BEFORE the primary analysis in patients with moderate to severe rheumatoid arthritis (combined Simponi 50 and 100 mg + MTX groups vs MTX alone for ACR50) was not statistically significant at week 24 (p = 0.053).
V študiji GO-BEFORE primarne analize pri bolnikih z zmernim do hudim revmatoidnim artritisom (skupno za skupini, ki sta prejemali zdravilo Simponi 50 mg in 100 mg z metotreksatom, v primerjavi s skupino, ki je prejemala samo metotreksat za ACR50) v 24. tednu niso bile statistično značilne (p = 0,053).
In GO-FORWARD and GO-AFTER, clinically meaningful and statistically significant responses in Disease Activity Scale (DAS)28 were observed at each prespecified time point, at week 14 and at week 24 (p ≤ 0.001).
V študijah GO-FORWARD in GO-AFTER so opazili klinično pomembne in statistično značilne odzive na lestvici aktivnosti bolezni (Disease Activity Scale – DAS 28) ob vsaki predhodno določeni časovni točki, v 14. tednu in v 24. tednu (p ≤ 0,001).
In GO-FORWARD clinically meaningful and statistically significant improvements were demonstrated in health-related quality of life as measured by the physical component score of the SF-36 in patients treated with Simponi versus placebo at week 24.
Pri bolnikih, zdravljenih z zdravilom Simponi, je bilo značilno več izboljšanj z zdravjem povezane kakovosti življenja, ocenjene z ASQoL, EQ-5D ter telesno in duševno komponento SF-36, kot pri bolnikih, ki so prejemali placebo.
In GO-FORWARD, among 89 subjects randomised to Simponi 50 mg + MTX, 48 were still on this treatment at week 104.
V študiji GO-FORWARD med 89 preiskovanci, ki so bili naključno razvrščeni v skupino, ki je prejemala 50 mg zdravila Simponi in metotreksat, jih je v 104. tednu 48 še vedno prejemalo to zdravljenje.
In gouty arthritis, both studies showed that Ilaris was more effective than triamcinolone acetonide at reducing pain intensity.
Pri protinskem artritisu sta obe študiji pokazali, da je pri zniževanju intenzivnosti bolečine zdravilo Ilaris učinkovitejše od triamcinolon acetonida.
In gouty arthritis, Ilaris was studied in two main studies involving 454 patients who were given either Ilaris or another anti-inflammatory medicine (triamcinolone acetonide) for 12 weeks.
Pri protinskem artritisu so zdravilo Ilaris proučevali v dveh glavnih študijah, v kateri je bilo vključenih 454 bolnikov, ki so 12 tednov prejemali zdravilo Ilaris ali drugo protivnetno zdravilo (triamcinolon acetonid).
In gouty arthritis, treatment with Ilaris should be started and supervised by a specialist doctor experienced in diagnosing and treating gouty arthritis and in the use of biological medicines.
Pri protinskem artritisu mora zdravljenje z zdravilom Ilaris uvesti in nadzirati zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem protina in uporabo bioloških zdravil.
In growing rats, there was no evidence of impaired mineralization even at doses greater than 5,000 times the dose required for osteoporosis treatment.
Pri rastočih podganah niso našli dokazov o motnji mineralizacije tudi pri odmerkih, ki so bili 5.000-krat večji od odmerkov, potrebnih za zdravljenje osteoporoze.
In HAE levels of a substance in your bloodstream called bradykinin are increased and this leads tosymptoms like swelling, pain, nausea, and diarrhoea.
Pri HAE je v krvnem obtoku povečana raven snovi, imenovane bradikinin, ki povzroča simptome, kot so oteklina, bolečina, navzea (slabost) in driska.
In haemodialysed patients, the posology should be adjusted so that Ketek 800 mg is given after the dialysis session (see also section 5.2).
Bolnikom na hemodializi je odmerjanje treba prilagoditi tako, da dobijo Ketek 800 mg po dializi (glejte poglavje 5.2)
In haemodialysed patients, until vaccination has become effective.
pri bolnikih na hemodializi, dokler cepivo ne postane učinkovito,
In haemodialysis patients and persons with an impaired immune system, adequate anti-HAV and anti-HBs antibody titres may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine.
Pri bolnikih na hemodializi in osebah s slabšim imunskim odzivom po osnovnem cepljenju morda ne bo dosežen ustrezen titer protiteles anti- HAV in anti-HBs, zato bodo tovrstni bolniki morda potrebovali dodatne odmerke cepiva.
In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.
V hemodinamskih študijah amlodipin uporabljen v območju terapevtskih odmerkov pri intaktnih živalih in pri ljudeh, ni bil povezan z negativnim inotropnim učinkom, niti v primeru sočasne uporabe z zaviralci receptorjev beta pri ljudeh.
In haemophilia, the dose is 90 micrograms per kilogram body weight, repeated every two to three hours until the bleeding is controlled.
Pri hemofiliji se daje odmerek 90 mikrogramov na kilogram telesne mase vsake dve do tri ure, dokler se ne vzpostavi nadzor nad krvavitvijo.
In half of the 16 patients who did not meet the criterion for maintained efficacy on UPDRS Part II+III score, the change from baseline was considered not clinically relevant.
Pri polovici od 16 bolnikov, pri katerih ni bilo izpolnjeno merilo za ohranitev učinkovitosti pri oceni z lestvico UPDRS, II. in III. del, sprememba v primerjavi z izhodiščno oceno ni bila klinično pomembna.
In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Pri HBeAg negativnih bolnikih brez ciroze naj zdravljenje traja najmanj do HBs serokonverzije ali do dokazane izgube učinkovitosti.
In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Pri HBeAg negativnih bolnikih brez ciroze naj zdravljenje traja najmanj do HBs serološke konverzije ali do dokazane izgube učinkovitosti.
In HBeAg positive adult patients, treatment should be administered at least until 12 months after achieving HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection on two consecutive serum samples at least 3-6 months apart) or until HBs seroconversion or there is loss of efficacy (see section 4.4).
 Pri HBeAg pozitivnih odraslih bolnikih mora zdravljenje trajati še vsaj 12 mesecev po doseženi serokonverziji HBe (izginotje HBeAg in HBV DNA ter pojav protiteles anti-HBe v dveh zaporednih vzorcih seruma, odvzetih z vsaj 3- do 6-mesečnim vmesnim presledkom) ali do serokonverzije HBs, oziroma do izgube učinkovitosti (glejte poglavje 4.4).
In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy (see section 4.4).
Pri HBeAg pozitivnih bolnikih brez ciroze naj zdravljenje traja najmanj 6-12 mesecev po potrditvi HBe serokonverzije (izguba HBeAg in izguba HBV DNA z detekcijo anti-HBe) ali do HBs serokonverzije ali dokler ne pride do izgube učinkovitosti (glejte poglavje 4.4).
In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy (see section 4.4).
Pri HBeAg pozitivnih bolnikih brez ciroze naj zdravljenje traja najmanj 6-12 mesecev po potrditvi HBe serološke konverzije (izguba HBeAg in izguba HBV DNA z detekcijo anti-HBe) ali do HBs serološke konverzije ali dokler ne pride do izgube učinkovitosti (glejte poglavje 4.4).
In HBeAg-negative patients without cirrhosis, treatment should be administered at least until HBsAg seroconversion or until there is evidence of loss of efficacy.
Pri HBeAg-negativnih bolnikih brez ciroze je treba zdravljenje izvajati vsaj do serokonverzije HBsAg ali do dokazanega prenehanja učinka zdravljenja.
In HBeAg-negative patients, telbivudine was non-inferior to lamivudine (75.2% and 77.2% responders; p = 0.6187).
Pri HBeAg- negativnih bolnikih telbivudin ni bil slabši kot lamivudin (75,2% bolnikov z odzivom v primerjavi s 77,2% ob lamivudinu; p = 0,6187).